NEW YORK (GenomeWeb News) – Medical & Biological Laboratories today announced it has signed a non-exclusive agreement with Envoy Therapeutics to provide it access to MBL's RIP-Chip technology.
Under the terms of the deal, MBL will receive an upfront payment of an undisclosed amount, annual licensing fees and potential milestone payments. Envoy will use the RIP-Chip for drug discovery and development.
Further terms of the deal were not disclosed.